Not Tagged
Not Tagged
['sclc', 'nsclc', 'improve']
today at #asco22: fda pooled analysis of 1l patients with advanced nsclc and pd-l1 50% suggests most subgroups receiving chemo-io regimens have improved or comparable os and pfs outcomes vs those receiving io-only regimens 
Real time, on-demand personalized cancer education and support through our online educational platform